We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.

Advertisement
Xencor and Roche Extend XmAb™ Antibody Therapeutics Collaboration
News

Xencor and Roche Extend XmAb™ Antibody Therapeutics Collaboration

Xencor and Roche Extend XmAb™ Antibody Therapeutics Collaboration
News

Xencor and Roche Extend XmAb™ Antibody Therapeutics Collaboration

Read time:
 

Want a FREE PDF version of This News Story?

Complete the form below and we will email you a PDF version of "Xencor and Roche Extend XmAb™ Antibody Therapeutics Collaboration"

First Name*
Last Name*
Email Address*
Country*
Company Type*
Job Function*
Would you like to receive further email communication from Technology Networks?

Technology Networks Ltd. needs the contact information you provide to us to contact you about our products and services. You may unsubscribe from these communications at any time. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy

Xencor, Inc. has announced an extension to its research collaboration with Roche to create monoclonal antibodies with differentiated pharmacological profiles.

Roche and Xencor entered into an initial collaboration in January 2005, in which Roche applies Xencor's XmAb Fc domains with the aim of enhancing the therapeutic efficacy of an antibody against a cancer target.

"We are very pleased to continue working with Roche to apply our XmAb proprietary engineered Fc domains to enhance the efficacy of Roche's proprietary antibodies," said Bassil Dahiyat, Ph.D., President and CEO of Xencor.

Under the original collaboration, Xencor received technology access and license fees, and is eligible to receive additional license fees, milestones and royalties in the event that Roche advances candidates into development. Xencor will receive additional fees for the extension.

Advertisement